Funding

PART a: IDENTIFICATION OF R&D Result

·        The project team

 

SECTION I: ESTIMATION OF COSTS

 

1

Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result.
… in terms of IPR protection
The patent family is based on patent application publication number WO2008HU00028 20080307. The European national phase is currently in progress.

 

 

…in terms of product development
Two senior professionals and two technicians will work three year’s on it. 150.000 EUR

 

 

…in terms of mass production
 

 

 

 

… in terms of marketing
 

 

 

2

Based on the above assessment as well as the marketing information please provide the correct estimation of the price for R&D product in correlation with costs

Year 1

Year 2

Year 3

Year 4

Year 5

Fixed costs

Personnel

Other running costs

Marketing costs

TOTAL EXPECTED COSTS

Price per Unit

Type of Unit

Number of Units

TOTAL Expected Revenues

CASH FLOW REQUIRED (REVENUES-COSTS)

TOTAL CAPITAL required for five years

 

 

SECTION 2: QUALITATIVE FACTORS

 

3

Dimension of identified target groups
 

 

 

 

 

 

4

Evaluation of financial Risks for R&D result
The invention is good, for other proteins too, but this should start from the beginning of the work. The university has all the necessary instrumentation for it.

It requires a further three year development to reach the industrial technology for this solution. It has high risk.

 

 

 

 

 

 

 

 

SECTION 3: IDENTIFICATION OF FINANCING SOURCES

After evaluating all the above mentioned criteria, please tick the best financing source for the achievement of R&D result (i.e. own capitals, banking credits, venture capital, business angels, etc)

 

1. European Funding

Define relevance of the product with the following potential funding sources and comment

1.

2.

3.

4.

 

2. National Funding

1.

2.

3.

 

3. Private funding

  1. 1.  venture capital

2.

3.

 

4. Other

 

 

SECTION 3: FINAL EVALUATION

It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)…
 The invention is a novel method of core-shell nanoparticle preparation of protein drugs or protein-bound active compounds, which provides a relatively easy and inexpensive way to formulate sustained release products.

Benefits of the novel method of core-shell nanoparticle preparation of protein drugs or protein-bound active compounds:

‒          provides a relatively easy method

‒          provides a relatively inexpensive method

‒          particles are in the nano size range

‒          sustained release benefits for patients (avoiding sudden large concentration, rare dosage, improved effects, and comfort)

‒          economical (installation efficiency of the protein drug superior to that of infiltration method)

 

Industrial-scale manufacturing is in progress.

They are looking for producers and/or a product developer to acquire the patent rights through an in-licence agreement.

 

 

Decision of evaluation (Please keep only the appropriate)

  • The R&D has a high potential of exploitation

 

Bookmark the permalink. Follow any comments here with the RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

Post a Comment

You must be logged in to post a comment.

Request a proposal

Valorisation Plan Authors

Related Documents

There in no related documents

Visit the other applications of the INTERVALUE Platform: R&D Repository | IP Agreements

© 2009-2010 INTERVALUE Project